RESUMEN
The current pandemic raises substantive ethical and legal challenges for inpatient psychiatric units striving simultaneously to contain COVID-19 and provide safe, high-quality psychiatric care. Among these challenges, psychiatric units need to consider their role in isolating and quarantining COVID-19 positive patients who are psychiatrically cleared for discharge. We examine this complex dilemma by evaluating mental health law, quarantine law, public health ethics, a case from an urban academic medical center's inpatient unit, and literature focused on treatment and isolation protocols during HIV and tuberculosis epidemics. Although inpatient units are highly restrictive and intended for acute psychiatric treatment, at present there are no obvious isolation, quarantine, or housing options for many patients with mental illness infected with COVID-19.
Asunto(s)
COVID-19 , Humanos , Pandemias , Alta del Paciente , Cuarentena , SARS-CoV-2Asunto(s)
COVID-19/prevención & control , Portador Sano/diagnóstico , Atención a la Salud , Control de Infecciones/métodos , Trastornos Mentales/terapia , Equipo de Protección Personal , Servicio de Psiquiatría en Hospital , Psicoterapia , Centros Médicos Académicos , COVID-19/diagnóstico , COVID-19/transmisión , Portador Sano/transmisión , Punto Alto de Contagio de Enfermedades , Unidades Hospitalarias , Humanos , Pacientes Internos , Máscaras , Tamizaje Masivo , Ciudad de Nueva York , Aislamiento de Pacientes , Distanciamiento Físico , SARS-CoV-2 , Comunicación por VideoconferenciaRESUMEN
Primary ciliary dyskinesia (PCD) is an inherited ciliopathy leading to chronic suppurative lung disease, chronic rhinosinusitis, middle ear disease, sub-fertility and situs abnormalities. As PCD is rare, it is important that scientists and clinicians foster international collaborations to share expertise in order to provide the best possible diagnostic and management strategies. 'Better Experimental Approaches to Treat Primary Ciliary Dyskinesia' (BEAT-PCD) is a multidisciplinary network funded by EU COST Action (BM1407) to coordinate innovative basic science and clinical research from across the world to drive advances in the field. The fourth and final BEAT-PCD Conference and fifth PCD Training School were held jointly in March 2019 in Poznan, Poland. The varied program of plenaries, workshops, break-out sessions, oral and poster presentations were aimed to enhance the knowledge and skills of delegates, whilst also providing a collaborative platform to exchange ideas. In this final BEAT-PCD conference we were able to build upon programmes developed throughout the lifetime of the COST Action. These proceedings report on the conference, highlighting some of the successes of the BEAT-PCD programme.